Structure Therapeutics Inc. (NASDAQ:GPCR) Holdings Increased by Deep Track Capital LP

Deep Track Capital LP lifted its holdings in shares of Structure Therapeutics Inc. (NASDAQ:GPCR - Free Report) by 129.4% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 2,800,000 shares of the company's stock after buying an additional 1,579,492 shares during the period. Structure Therapeutics comprises 2.8% of Deep Track Capital LP's holdings, making the stock its 11th largest position. Deep Track Capital LP owned approximately 4.89% of Structure Therapeutics worth $75,936,000 as of its most recent SEC filing.

Several other large investors also recently modified their holdings of GPCR. Boxer Capital Management LLC bought a new stake in shares of Structure Therapeutics during the 4th quarter worth approximately $13,560,000. Marshall Wace LLP lifted its holdings in Structure Therapeutics by 339.6% in the fourth quarter. Marshall Wace LLP now owns 583,207 shares of the company's stock valued at $15,817,000 after buying an additional 450,531 shares during the period. Foresite Capital Management VI LLC bought a new position in shares of Structure Therapeutics during the 4th quarter worth approximately $11,390,000. Principal Financial Group Inc. boosted its holdings in Structure Therapeutics by 230.0% in the third quarter. Principal Financial Group Inc. now owns 545,359 shares of the company's stock worth $23,936,000 after acquiring an additional 380,115 shares in the last quarter. Finally, Ameriprise Financial Inc. increased its position in shares of Structure Therapeutics by 29.4% during the fourth quarter. Ameriprise Financial Inc. now owns 1,420,052 shares of the company's stock worth $38,512,000 after acquiring an additional 322,601 shares in the last quarter. 91.78% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

GPCR has been the subject of a number of research analyst reports. HC Wainwright decreased their price objective on shares of Structure Therapeutics from $80.00 to $75.00 and set a "buy" rating for the company in a report on Monday. William Blair initiated coverage on Structure Therapeutics in a research report on Friday, February 28th. They issued an "outperform" rating for the company. Finally, Citigroup began coverage on Structure Therapeutics in a research note on Friday, May 2nd. They issued a "buy" rating and a $60.00 target price for the company. Nine research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Structure Therapeutics has an average rating of "Buy" and an average price target of $78.00.

Structure Therapeutics Stock Up 0.2%

NASDAQ:GPCR traded up $0.05 on Monday, hitting $25.62. The stock had a trading volume of 200,111 shares, compared to its average volume of 925,992. The stock has a market cap of $1.47 billion, a price-to-earnings ratio of -34.62 and a beta of -1.69. Structure Therapeutics Inc. has a 1-year low of $13.22 and a 1-year high of $62.74. The company has a fifty day moving average price of $20.94 and a two-hundred day moving average price of $26.87.

Structure Therapeutics (NASDAQ:GPCR - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The company reported ($0.27) EPS for the quarter, missing the consensus estimate of ($0.24) by ($0.03). As a group, analysts anticipate that Structure Therapeutics Inc. will post -0.82 earnings per share for the current year.

About Structure Therapeutics

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.